Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.66
STEM's Cash to Debt is ranked higher than
60% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. STEM: 1.66 )
STEM' s 10-Year Cash to Debt Range
Min: 0.66   Max: 63.74
Current: 1.66

0.66
63.74
Equity to Asset 0.21
STEM's Equity to Asset is ranked higher than
51% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. STEM: 0.21 )
STEM' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.83
Current: 0.21

0.1
0.83
F-Score: 3
Z-Score: -14.99
M-Score: -4.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -2377.81
STEM's Operating margin (%) is ranked higher than
54% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. STEM: -2377.81 )
STEM' s 10-Year Operating margin (%) Range
Min: -50159.65   Max: -63.56
Current: -2377.81

-50159.65
-63.56
Net-margin (%) -2197.76
STEM's Net-margin (%) is ranked higher than
54% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. STEM: -2197.76 )
STEM' s 10-Year Net-margin (%) Range
Min: -43900   Max: -75.42
Current: -2197.76

-43900
-75.42
ROE (%) -176.80
STEM's ROE (%) is ranked higher than
52% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. STEM: -176.80 )
STEM' s 10-Year ROE (%) Range
Min: -448.06   Max: -19.6
Current: -176.8

-448.06
-19.6
ROA (%) -63.62
STEM's ROA (%) is ranked higher than
58% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. STEM: -63.62 )
STEM' s 10-Year ROA (%) Range
Min: -99.54   Max: -15.67
Current: -63.62

-99.54
-15.67
ROC (Joel Greenblatt) (%) -539.21
STEM's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. STEM: -539.21 )
STEM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1639.71   Max: -19.13
Current: -539.21

-1639.71
-19.13
Revenue Growth (%) -37.00
STEM's Revenue Growth (%) is ranked higher than
61% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. STEM: -37.00 )
STEM' s 10-Year Revenue Growth (%) Range
Min: -81.5   Max: 128.9
Current: -37

-81.5
128.9
EBITDA Growth (%) -33.70
STEM's EBITDA Growth (%) is ranked higher than
58% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. STEM: -33.70 )
STEM' s 10-Year EBITDA Growth (%) Range
Min: -33.7   Max: 9.6
Current: -33.7

-33.7
9.6
EPS Growth (%) -33.20
STEM's EPS Growth (%) is ranked higher than
61% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. STEM: -33.20 )
STEM' s 10-Year EPS Growth (%) Range
Min: -33.2   Max: 24.1
Current: -33.2

-33.2
24.1
» STEM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

STEM Guru Trades in Q2 2012

Jim Simons 729,079 sh (New)
» More
Q3 2012

STEM Guru Trades in Q3 2012

Jim Simons 536,200 sh (-26.46%)
» More
Q4 2012

STEM Guru Trades in Q4 2012

Jim Simons 24,300 sh (-95.47%)
» More
Q1 2013

STEM Guru Trades in Q1 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with STEM



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.50
STEM's P/B is ranked higher than
61% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. STEM: 12.50 )
STEM' s 10-Year P/B Range
Min: 1.64   Max: 22
Current: 12.5

1.64
22
P/S 65.36
STEM's P/S is ranked higher than
66% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. STEM: 65.36 )
STEM' s 10-Year P/S Range
Min: 6.61   Max: 2230
Current: 65.36

6.61
2230
EV-to-EBIT -2.96
STEM's EV-to-EBIT is ranked higher than
67% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. STEM: -2.96 )
STEM' s 10-Year EV-to-EBIT Range
Min: 17.4   Max: 27.6
Current: -2.96

17.4
27.6
Current Ratio 3.25
STEM's Current Ratio is ranked higher than
69% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. STEM: 3.25 )
STEM' s 10-Year Current Ratio Range
Min: 1.75   Max: 21.05
Current: 3.25

1.75
21.05
Quick Ratio 3.25
STEM's Quick Ratio is ranked higher than
71% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. STEM: 3.25 )
STEM' s 10-Year Quick Ratio Range
Min: 1.75   Max: 21.05
Current: 3.25

1.75
21.05

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 24.70
STEM's Price/Tangible Book is ranked higher than
62% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. STEM: 24.70 )
STEM' s 10-Year Price/Tangible Book Range
Min: 0.85   Max: 23.75
Current: 24.7

0.85
23.75
Price/Median PS Value 0.20
STEM's Price/Median PS Value is ranked higher than
99% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. STEM: 0.20 )
STEM' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 10.6
Current: 0.2

0.01
10.6
Earnings Yield (Greenblatt) 557.70
STEM's Earnings Yield (Greenblatt) is ranked higher than
96% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. STEM: 557.70 )
STEM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.6   Max: 823.9
Current: 557.7

3.6
823.9
Forward Rate of Return (Yacktman) -111.42
STEM's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. STEM: -111.42 )
STEM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -32.8   Max: -28.6
Current: -111.42

-32.8
-28.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CY9A.Germany
StemCells, Inc. is a Delaware Corporation. The Company is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. It is focused on cellular medicine, or the use of stem and progenitor cells as the basis for novel therapeutics and therapies, and enabling technologies for stem cell research, or the use of cells and related technologies to enable stem cell-based research and drug discovery and development. The Company's primary research and development efforts are focused on cellular medicine, where it seeks to identify and develop stem and progenitor cells as potential therapeutic agents. It currently has two therapeutic product development programs: its CNS Program, which is developing applications for HuCNS-SC cells, its proprietary human neural stem cell product candidate, and its Liver Program, which is developing applications for its proprietary human liver engrafting cells. It currently markets a range of proprietary cell culture products under the SC Proven brand, including iSTEM, GS1-RTM, GS2-MTM, RHB-A, RHB-Basal, NDiff, N2B27, NDiff, 2 and 27 supplements, HEScGROTM, and ESGRO CompleteTMproprietary media. The Company's primary strategy is to identify multiple types of human stem and progenitor cells with therapeutic and commercial importance, to develop techniques and processes to purify these cells for direct transplant and to expand and bank these cells, to advance these cells into clinical development and ultimately, to commercialize them as cell-based therapeutic products. The Company's research and development activities and the future manufacturing and marketing of its potential therapeutic products are, and would continue to be, subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.
» More Articles for STEM

Headlines

Articles On GuruFocus.com
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
comment on STEM Feb 09 2012 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
StemCells Inc. Reports Operating Results (10-Q) Nov 03 2010 
StemCells Inc. Reports Operating Results (10-Q) May 04 2010 
StemCells Inc. Reports Operating Results (10-Q) Nov 05 2009 
StemCells, Inc. Reports Second Quarter Financial Results Aug 10 2009 
StemCells Inc. Reports Operating Results (10-Q) Aug 10 2009 
The Next Boom Emerges Nov 23 2008 

More From Other Websites
STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 22 2014
StemCells, Inc. Announces Closing of $20 Million Offering Jul 18 2014
StemCells, Inc. Announces Closing of $20 Million Offering Jul 18 2014
STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 15 2014
Why StemCells (STEM) Stock Is Down Today Jul 15 2014
StemCells, Inc. Announces Proposed $20 Million Offering Jul 15 2014
StemCells, Inc. Announces Proposed $20 Million Offering Jul 15 2014
STEMCELLS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events Jul 08 2014
StemCells, Inc. Appoints Dr. Alan Trounson to Board of Directors Jul 07 2014
StemCells, Inc. Appoints Dr. Alan Trounson to Board of Directors Jul 07 2014
It’s time to stem the loss of STEM graduates Jul 06 2014
Stock Downgrades: Declare Your Independence From Regado Biosciences Jul 03 2014
Why StemCells (STEM) Stock Is Gaining Today Jul 02 2014
Coverage initiated on StemCells by Brinson Patrick Jul 02 2014
StemCells (STEM) Is Today's Perilous Reversal Stock Jun 26 2014
Medical Action Industries Leads Healthcare Sector; Aerie Pharmaceutical Meets Clinical Endpoints Jun 25 2014
General Mills Tumbles On Downbeat Earnings; Barnes & Noble Shares Spike Higher Jun 25 2014
Brainstorm Cell Therapeutics, Inc.: A Small Biotech With Big Plans And Huge Potential Jun 24 2014
StemCells, Inc. President and CEO Martin McGlynn to Present on a Regenerative Medicine Panel at the... Jun 23 2014
Mid-Afternoon Market Update: Oracle Shares Fall; Shire Shares Climb Jun 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide